Compare Eli Lilly And Co (LLY) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

TCPC trades at $3.21, down 3.02% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025, though it maintains a 112% net income margin due to accounting adjustments. Recent news includes a Zacks upgrade to Buy and an upcoming Q2 2026 earnings report on August 6, 2026.

Outlook remains cautious with mixed analyst sentiment (30.77% Buy) and ongoing legal scrutiny. The stock's low P/B of 0.49 suggests potential value, but persistent losses and negative cash flow pose significant risks. Dividend sustainability is a key concern amid financial pressures.